The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Clinical Trial
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results. ⋯ Adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas adjuvant chemoradiotherapy has a deleterious effect on survival.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Tamoxifen, taken for five years, is the standard adjuvant treatment for postmenopausal women with primary, estrogen-receptor-positive breast cancer. Despite this treatment, however, some patients have a relapse. ⋯ Exemestane therapy after two to three years of tamoxifen therapy significantly improved disease-free survival as compared with the standard five years of tamoxifen treatment.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.
Calcitonin gene-related peptide (CGRP) may have a causative role in migraine. We therefore hypothesized that a CGRP-receptor antagonist might be effective in the treatment of migraine attacks. ⋯ The CGRP antagonist BIBN 4096 BS was effective in treating acute attacks of migraine.